Navigation Links
Breckenridge Pharmaceutical Signs Letter of Intent for Long Term Agreement With Orit Laboratories (West Caldwell, NJ)
Date:4/10/2008

BOCA RATON, Fla., April 10 /PRNewswire/ -- Breckenridge announced today that it has entered into an agreement with Orit Laboratories to market 2 separate generic ANDA products. The first project is currently filed and pending FDA approval. The companies plan to file an ANDA with the FDA for the second product in the 3rd Quarter of 2008. Upon approval by the FDA, both products will be supplied by Orit Laboratories, and will be marketed and distributed by Breckenridge Pharmaceutical, Inc., on an exclusive basis in the USA.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand(TM) and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, including multiple ANDA's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. http://www.bpirx.com

About Orit Laboratories:

Orit Laboratories specializes in the development of specialty generic pharmaceutical prescription products. The company focuses on the development of solid, liquid, soft gelatin capsule, modified release, and orally disintegrating dosage formulations using proprietary Drug Delivery Platforms. Orit Laboratories operates an FDA registered cGMP facility in West Caldwell, New Jersey that is approximately 10,000 sq. ft. The company is capable of pilot scale production, and their analytical laboratory operates under cGMP & cGLP. Orit has capabilities of Regulatory filing with the US Food and Drug Administration (FDA).


'/>"/>
SOURCE Breckenridge Pharmaceutical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Breckenridge Pharmaceutical Enters Agreement With Helm AG (Hamburg, Germany) to Develop Additional ANDA Project
2. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
3. Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
4. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
5. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
6. China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.
7. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
8. KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping ... fitness app. The fitness app plans to fix the two major problems leading the fitness ... size fits all type program , They don’t eliminate all the reasons people ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American Institutes ... Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , ... advance care planning, healthcare costs and patient and family engagement. , AIR researchers ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
Breaking Medicine Technology: